Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer.

Surgery - 1 Oct 2015

Batchu Ramesh B, Gruzdyn Oksana V, Qazi Aamer M, Kaur Jaskiran, Mahmud Ebrahem M, Weaver Donald W, Gruber Scott A

Abstract excerpt

PURPOSE: MicroRNA (miR)-26a has been identified as a tumor suppressor in pancreatic cancer cells. Although wild-type p53 controls cell-cycle progression, its mutant form normally present in pancreatic cancer loses this capability. Phosphorylation is known to restore wild-type activity to mutant p53. We, therefore, examined whether miR-26a treatment can restore wild-type functions of mutant p53 via...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blotting, Western
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle

Share to Cell Movement

Share to MicroRNAs

Share to Neoplastic Stem Cells

Share to Pancreatic Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 26189069
DOI: 10.1016/j.surg.2015.05.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer.PMID 26189069Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

CDK14/β-catenin/TCF4/miR-26b positive feedback regulation modulating pancreatic cancer cell phenotypes in vitro and tumor growth in mice model in vivo.Semantic proximity Read ↗

Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21Semantic proximity Read ↗

Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer CellsSemantic proximity Read ↗

Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 LevelsSemantic proximity Read ↗

Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53.Semantic proximity Read ↗

Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.Semantic proximity Read ↗

[6]-Gingerol induces cell cycle arrest and cell death of mutant p53-expressing pancreatic cancer cells.Semantic proximity Read ↗

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA DamageSemantic proximity Read ↗

p8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growth.Semantic proximity Read ↗

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53Semantic proximity Read ↗

A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.